Drug problems
BY ALB, Reuters |
Ben Hirschler of Reuters investigates how GlaxoSmithKline missed all the red flags in China. Michael Martina of Reuters finds that compliance is now the buzzword for foreign firms in China after Glaxo. And Ben Hirschler, Ransdell Pierson and Kazunori Takada report on why China pays too much for medicines. Also, a timeline of the GSK scandal.